- Home
- QNRX vs ADTX Comparison
QNRX vs ADTX Comparison
Compare QNRX & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- ADTX
- Stock Information
- Founded
- QNRX 2018
- ADTX 2017
- Country
- QNRX United States
- ADTX United States
- Employees
- QNRX N/A
- ADTX N/A
- Industry
- QNRX Medical/Dental Instruments
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- ADTX Health Care
- Exchange
- QNRX Nasdaq
- ADTX Nasdaq
- Market Cap
- QNRX 5.3M
- ADTX 5.3M
- IPO Year
- QNRX N/A
- ADTX 2020
- Fundamental
- Price
- QNRX $0.57
- ADTX $0.13
- Analyst Decision
- QNRX Strong Buy
- ADTX
- Analyst Count
- QNRX 1
- ADTX 0
- Target Price
- QNRX $4.00
- ADTX N/A
- AVG Volume (30 Days)
- QNRX 1.4M
- ADTX 39.3M
- Earning Date
- QNRX 03-12-2025
- ADTX 11-18-2024
- Dividend Yield
- QNRX N/A
- ADTX N/A
- EPS Growth
- QNRX N/A
- ADTX N/A
- EPS
- QNRX N/A
- ADTX N/A
- Revenue
- QNRX N/A
- ADTX $212,107.00
- Revenue This Year
- QNRX N/A
- ADTX $95.61
- Revenue Next Year
- QNRX N/A
- ADTX $1,584.79
- P/E Ratio
- QNRX N/A
- ADTX N/A
- Revenue Growth
- QNRX N/A
- ADTX N/A
- 52 Week Low
- QNRX $0.43
- ADTX $0.12
- 52 Week High
- QNRX $6.18
- ADTX $218.00
- Technical
- Relative Strength Index (RSI)
- QNRX 43.80
- ADTX 18.05
- Support Level
- QNRX $0.56
- ADTX $0.12
- Resistance Level
- QNRX $0.63
- ADTX $0.21
- Average True Range (ATR)
- QNRX 0.07
- ADTX 0.03
- MACD
- QNRX -0.00
- ADTX 0.03
- Stochastic Oscillator
- QNRX 11.56
- ADTX 9.91
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.